Matthew E. Ros's most recent trade in Jasper Therapeutics Inc was a trade of 881 Non-Voting Convertible Preferred Stock done . Disclosure was reported to the exchange on July 20, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Jasper Therapeutics Inc | Matthew E. Ros | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 20 Jul 2026 | 881 | 881 | - | - | Non-Voting Convertible Preferred Stock | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2026 | 17,901 | 17,901 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jun 2025 | 44,700 | 44,700 | - | - | Stock Option (Right to Buy) | |
| Verastem Inc | Matthew E. Ros | Chief Operating Officer | 01 Apr 2025 | 50,000 | 50,000 (0%) | 0% | 0 | Common Stock | ||
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 44,700 | 44,700 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 3,051 | 3,051 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jul 2023 | 1,743 | 1,743 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2023 | 36,700 | 36,700 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Apr 2023 | 1,900 | 1,900 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2023 | 1,792 | 1,792 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Oct 2022 | 1,419 | 1,419 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2022 | 2,194 | 2,194 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jun 2022 | 30,700 | 30,700 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Apr 2022 | 2,650 | 2,650 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 2,256 | 2,256 | - | - | Stock Option (Right to Buy) | |
| Cogent Biosciences Inc | Matthew E. Ros | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2021 | 2,463 | 2,463 | - | - | Stock Option (Right to Buy) |